New psoriasis therapies must demonstrate value.

The article discusses the cost of psoriasis in the U.S. due to medical expenses and lost wages, according to the National Psoriasis Foundation (NPS). Topics discussed include comments from Kimberly White of firm Numerof & Associates, regarding the Consumer Price Index with the increased prices for these products, Michael J. Sax of the Pharmacy Group (TPG), regarding increased interest of managed care in controlling costs due to therapeutic options for psoriasis and help to patients with drugs.